The University of Chicago Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Derek Wainwright and Kristen Lauing.
Derek Wainwright
Connection Strength
3.948
Kristen Lauing
  1. Age-stratified comorbid and pharmacologic analysis of patients with glioblastoma. Brain Behav Immun Health. 2024 Jul; 38:100753.
    View in: PubMed
    Score: 0.248
  2. Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence. Clin Cancer Res. 2023 12 01; 29(23):4973-4989.
    View in: PubMed
    Score: 0.243
  3. Identification and Characterization of a Novel Indoleamine 2,3-Dioxygenase 1 Protein Degrader for Glioblastoma. J Med Chem. 2022 12 08; 65(23):15642-15662.
    View in: PubMed
    Score: 0.227
  4. A systematic review of pharmacologic treatment efficacy for depression in older patients with cancer. Brain Behav Immun Health. 2022 May; 21:100449.
    View in: PubMed
    Score: 0.217
  5. Glioblastoma as an age-related neurological disorder in adults. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab125.
    View in: PubMed
    Score: 0.208
  6. Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies. Front Immunol. 2020; 11:1185.
    View in: PubMed
    Score: 0.192
  7. A retrospective survival analysis of Glioblastoma patients treated with selective serotonin reuptake inhibitors. Brain Behav Immun Health. 2020 Feb; 2.
    View in: PubMed
    Score: 0.185
  8. Quantification of IDO1 enzyme activity in normal and malignant tissues. Methods Enzymol. 2019; 629:235-256.
    View in: PubMed
    Score: 0.180
  9. The Coincidence Between Increasing Age, Immunosuppression, and the Incidence of Patients With Glioblastoma. Front Pharmacol. 2019; 10:200.
    View in: PubMed
    Score: 0.176
  10. The interplay among psychological distress, the immune system, and brain tumor patient outcomes. Curr Opin Behav Sci. 2019 Aug; 28:44-50.
    View in: PubMed
    Score: 0.175
  11. Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017). Oncoimmunology. 2019; 8(3):1548242.
    View in: PubMed
    Score: 0.173
  12. Lessons learned from rindopepimut treatment in patients with EGFRvIII-expressing glioblastoma. Transl Cancer Res. 2018 Apr; 7(Suppl 4):S510-S513.
    View in: PubMed
    Score: 0.164
  13. IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma. Clin Cancer Res. 2018 06 01; 24(11):2559-2573.
    View in: PubMed
    Score: 0.163
  14. IDO1 in cancer: a Gemini of immune checkpoints. Cell Mol Immunol. 2018 May; 15(5):447-457.
    View in: PubMed
    Score: 0.162
  15. Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma. Brain Behav Immun. 2017 May; 62:24-29.
    View in: PubMed
    Score: 0.152
  16. The Kynurenine/Tryptophan Ratio and Glioblastoma Patients Treated with Hsppc-96 Vaccine. Immunotherapy (Los Angel). 2016 Sep; 2(3).
    View in: PubMed
    Score: 0.148
  17. Advanced age negatively impacts survival in an experimental brain tumor model. Neurosci Lett. 2016 Sep 06; 630:203-208.
    View in: PubMed
    Score: 0.146
  18. Improving vaccine efficacy against malignant glioma. Oncoimmunology. 2016 Aug; 5(8):e1196311.
    View in: PubMed
    Score: 0.145
  19. Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy. Clin Cancer Res. 2015 Dec 15; 21(24):5427-33.
    View in: PubMed
    Score: 0.139
  20. The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy. J Clin Neurosci. 2015 Dec; 22(12):1964-8.
    View in: PubMed
    Score: 0.137
  21. The role of IDO in brain tumor immunotherapy. J Neurooncol. 2015 Jul; 123(3):395-403.
    View in: PubMed
    Score: 0.131
  22. Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry. J Immunother Cancer. 2022 07; 10(7).
    View in: PubMed
    Score: 0.055
  23. Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma. Clin Cancer Res. 2021 12 01; 27(23):6514-6528.
    View in: PubMed
    Score: 0.052
  24. Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma. Clin Cancer Res. 2020 10 01; 26(19):5232-5245.
    View in: PubMed
    Score: 0.048
  25. Indoleamine 2,3-dioxygenase 1 and overall survival of patients diagnosed with esophageal cancer. Oncotarget. 2018 May 04; 9(34):23482-23493.
    View in: PubMed
    Score: 0.041
  26. Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival. Clin Cancer Res. 2017 Nov 01; 23(21):6650-6660.
    View in: PubMed
    Score: 0.039
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.